Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
1P01AI060908-01A1
Application #
6966511
Study Section
Special Emphasis Panel (ZAI1-JB-M (M1))
Project Start
2005-07-01
Project End
2010-06-30
Budget Start
2005-07-01
Budget End
2006-06-30
Support Year
1
Fiscal Year
2005
Total Cost
$185,855
Indirect Cost
Name
Ordway Research Institute, Inc.
Department
Type
DUNS #
124361945
City
Albany
State
NY
Country
United States
Zip Code
12208
Heine, Henry S; Louie, Arnold; Adamovicz, Jeffrey J et al. (2014) Evaluation of imipenem for prophylaxis and therapy of Yersinia pestis delivered by aerosol in a mouse model of pneumonic plague. Antimicrob Agents Chemother 58:3276-84
Roberts, Jason A; Abdul-Aziz, Mohd H; Lipman, Jeffrey et al. (2014) Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis 14:498-509
Louie, Arnold; Vanscoy, Brian; Liu, Weiguo et al. (2013) Hollow-fiber pharmacodynamic studies and mathematical modeling to predict the efficacy of amoxicillin for anthrax postexposure prophylaxis in pregnant women and children. Antimicrob Agents Chemother 57:5946-60
Louie, Arnold; VanScoy, Brian D; Brown, David L et al. (2012) Impact of spores on the comparative efficacies of five antibiotics for treatment of Bacillus anthracis in an in vitro hollow fiber pharmacodynamic model. Antimicrob Agents Chemother 56:1229-39
Louie, Arnold; Vanscoy, Brian D; Heine 3rd, Henry S et al. (2012) Differential effects of linezolid and ciprofloxacin on toxin production by Bacillus anthracis in an in vitro pharmacodynamic system. Antimicrob Agents Chemother 56:513-7
Louie, A; Heine, H S; VanScoy, B et al. (2011) Use of an in vitro pharmacodynamic model to derive a moxifloxacin regimen that optimizes kill of Yersinia pestis and prevents emergence of resistance. Antimicrob Agents Chemother 55:822-30
Louie, Arnold; Vanscoy, Brian; Liu, Weiguo et al. (2011) Comparative efficacies of candidate antibiotics against Yersinia pestis in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 55:2623-8
Bulitta, Jurgen B; Landersdorfer, Cornelia B; Forrest, Alan et al. (2011) Relevance of pharmacokinetic and pharmacodynamic modeling to clinical care of critically ill patients. Curr Pharm Biotechnol 12:2044-61
Drusano, G L; Okusanya, O O; Okusanya, A O et al. (2009) Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis. Antimicrob Agents Chemother 53:4718-25
Louie, A; Heine, H S; Kim, K et al. (2008) Use of an in vitro pharmacodynamic model to derive a linezolid regimen that optimizes bacterial kill and prevents emergence of resistance in Bacillus anthracis. Antimicrob Agents Chemother 52:2486-96

Showing the most recent 10 out of 15 publications